Potential biomarkers of early pancreatic cancer discovered
the ONA take:
Patients with pancreatic cancer face a poor prognosis, as only approximately 6% of patients with pancreatic cancer survive more than 5 years after diagnosis.
The low survival rate is primarily because no reliable tools are available to make an early diagnosis, when tumors can be removed before they metastasize. A team at H. Lee Moffitt Cancer Center, in Tampa, Florida, may have found a potential biomarker for the disease.
Similar to ongoing work at other research centers, the Moffitt team is focusing on microRNAs, small molecules that control many cancer processes in the body.
The Moffitt team focused specifically on microRNAs linked to intraductal papillary mucinous neoplasms (IPMNs). IPMNs are a type of pancreatic cyst or lesion that can develop into pancreatic cancer the same way precancerous polyps in the colon develop into colon cancer.
These lesions can be seen on CT or MRI; however, imaging studies cannot determine if the lesions are benign or malignant. In addition, surgical resection of the lesions for biopsy can result in long-term diabetes or death. The Moffitt team identified six microRNAs that appeared to differentiate high-risk from low-risk lesions; they also appear to contribute to pancreatic cancer progression.
Researchers are hopeful that these findings will contribute to new ways of detecting the disease earlier and improving the poor prognosis for these patients.
Patients with pancreatic cancer face a poor prognosis, as only approximately 6% of patients survive.
- Physical Activity Improves Outcomes for Patients with Breast Cancer and Survivors
- Behavior Pain Assessment Tool Measures Pain In Patients Who Cannot Communicate Verbally
- Whole Genome Sequencing Reveals that 12% of Childhood Cancer Survivors Have Mutations in Genes that Increase Cancer Risk
- Increased 5-Year Survival Rate Seen in NSCLC Subset Treated With Nivolumab
- Novel Test For Multiple Myeloma Uses Microchip, Conventional Blood Sample
- Exercise, Psychological Interventions Better for Cancer Fatigue Than Medications
- ASCO Issues Global Guidance for HPV Vaccination for Cervical Cancer Prevention
- Discharge Events Improved With Standardized Inpatient Palliative Care Consultation
- Little Opposition to Early Palliative Care for Symptom Management in Pediatric Oncology
- Updated ASTRO Guideline Bolsters Safety, Efficacy of Palliative RT for Bone Metastases
- Thyroid Cancer Incidence Increasing Among Younger, Hispanic, African American Populations
- JAK1, JAK2 Inhibition Improves Outcomes in Myeloproliferative Neoplasms, But More Is Needed
- Recommendations Against Contralateral Prophylactic Mastectomy Not Tied to Patient Satisfaction
- Self-efficacy Level Predictive of Likelihood to Follow Through With Colorectal Cancer Screening
- Chronic Myeloproliferative Neoplasms Treatment (Fact Sheet)
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|